Specific-pathogen-free B6D2 F1 hybrid mice were treated orally with tilorone hydrochloride (100 mg/kg of body weight per day) and infected with sublethal doses of Listeria monocytogenes, Salmonella enteritidis, Mycobacterium bovis (BCG Pasteur), or M. tuberculosis Erdman. Daily tilorone treatment inhibited the cell-mediated response to all of the intracellular parasites, and most of the mice succumbed to the challenge. Tilorone suppressed delayed hypersensitivity responses to the microbial sensitins as well as to sheep erythrocytes. However, humoral responses (immediate hypersensitivity reactions) were stimulated. The types of growth curves obtained in the tilorone-treated mice were quite different from those observed in T-cell-depleted mice and tended to resemble those seen in sublethally irradiated (400 rads) animals. Leukocyte counts were depressed 10-fold by daily tilorone treatment. Both monocyte and granulocyte (but not largelymphocyte) counts were depressed. There was an initial drop in small-lymphocyte counts with a later recovery phase. Tilorone treatment reduced the granulomatous response within the Salmonella-infected liver, suggesting that the drug interferes with the mobilization of the mononuclear defenses within the normal host.
Specific-pathogen-free B6D2 F1 hybrid mice were treated orally with tilorone hydrochloride (100 mg/kg of body weight per day) and infected with sublethal doses of Listeria monocytogenes, Salmonella enteritidis, Mycobacterium bovis (BCG Pasteur), or M. tuberculosis Erdman. Daily tilorone treatment inhibited the cell-mediated response to all of the intracellular parasites, and most of the mice succumbed to the challenge. Tilorone suppressed delayed hypersensitivity responses to the microbial sensitins as well as to sheep erythrocytes. However, humoral responses (immediate hypersensitivity reactions) were stimulated. The types of growth curves obtained in the tilorone-treated mice were quite different from those observed in T-cell-depleted mice and tended to resemble those seen in sublethally irradiated (400 rads) animals. Leukocyte counts were depressed 10- fold by daily tilorone treatment. Both monocyte and granulocyte (but not largelymphocyte) counts were depressed. There was an initial drop in small-lymphocyte counts with a later recovery phase. Tilorone treatment reduced the granulomatous response within the Salmonella-infected liver, suggesting that the drug interferes with the mobilization of the mononuclear defenses within the normal host.
Tilorone is a fluorenone derivative with antiviral activity and an ability to induce interferon production in mice and rats exposed to oral doses of the drug (8) . Although tilorone increases resistance to a number of viral infections, it can potentiate microbial infections by interfering with the induction of the normal T-cell-mediated host response (3, 10) . Repeated daily dosage of this drug is associated with reduced tuberculin hypersensitivity, experimental allergic encephalomyelitis, and graft-versus-host, and adjuvant arthritis responses in appropriately sensitized rats (12, 13) . Histological examination of the tilorone-treated host reveals a striking cellular depletion within the thymus-dependent areas of the spleen and lymph mode (11) . No such effect occurred within the spleens of athymic mice treated with tilorone (9) . Acquired resistance to facultative intracellular parasites depends upon both immunocompetent T-lymphocytes and monocytes entering the developing focal lesions within the liver and spleen (4) . Earlier studies with Listeria and Salmonella-infected mice which had been treated with multiple oral doses of tilorone suggested that the normal cellular defense system had been compromised in some way (3, 10) . However, the shape of the resulting growth curves was quite different from those observed in athymic nude mice (1) or in adult thymectomized, irradiated, bone marrow-reconstituted mice (2) . This strongly suggests the involvement of other cells in the tilorone response; to explore this possibility further, a number of growth studies were carried out in mice in which the cell-mediated defenses had been modified by several different procedures and then compared with the effect of daily oral tilorone treatments.
MATERIALS AND METHODS Animals. Specific-pathogen-free C57BL/6 x DBA-2 (B6D2) F1 hybrid mice were bred and maintained at the Trudeau Animal Breeding Facility under conditions described previously (5) . Adult thymectomized, lethally irradiated, bone marrow-reconstituted (THXB) B6D2 mice, together with a small number of sham-thymectomized controls, were prepared as described elsewhere (5) . Sublethally irradiated mice were exposed to 400 rads of whole-body gamma irradiation 24 h before challenge (19 Leukocyte counts. Groups of five randomly selected mice were bled by heart puncture at daily intervals after the inception of the tilorone treatment regimen. Blood samples were diluted in saline, and the total number of leukocytes was determined by using a Coulter Counter model B (Coulter Electronics, Hialeah, Fla.). Air-dried smears of whole blood were stained with May-Grunwald Giemsa stain for the differential counts. Leukocyte concentrates were prepared where necessary, as described elsewhere (19) .
T-lymphocytes. T-lymphocytes were counted after exposure of the leukocyte concentrates to fluorescinated anti-thy 1.2 mouse antiserum (Accurate Chemical and Scientific Corp., Hicksville, N.Y.) and examined with a Zeiss epifluorescence microscope as described by Raff (17) .
B-lymphocytes. The leukocyte concentrates were treated with fluorescinated rabbit anti-mouse immunoglobulin G serum (Microbiological Associates, Bethesda, Md.) and examined under ultraviolet illumination (18) .
RESULTS
Growth of L. monocytogenes in tiloronetreated B6D2 mice. Normal B6D2 mice were treated orally with 100 mg of tilorone per kg 24 h before intravenous challenge with a sublethal dose of L. monocytogenes (2 x 103 to 5 X 103 viable bacteria suspended in 0.2 ml of saline). The mice continued to receive daily dosages of tilorone until the completion of the experiment. The Listeria challenge multiplied logarithmically in the liver and spleen for 2 to 3 days, at which time the normal controls developed an immune response which limited the further systemic growth of the organisms so that none of the mice died as a result of the challenge infection (Fig. 1) . The tilorone-treated mice showed continued logarithmic growth in both the liver and spleen until the counts reached lethal proportions (usually about day 5). None of the tilorone-treated mice exhibited significant levels of delayed hypersensitivity to the footpad test antigen (Fig. 1) . Normal controls developed highly significant 24-h footpad responses to the Listeria test antigen by day 5 of the infection.
The growth curves that developed in the tilorone-treated mice were quite different from those observed when the same inoculum was introduced into T-cell-depleted mice (Fig. 1 ). The Listeria growth curves in the THXB mice exhibited a characteristic slow increase in viable counts for both the liver and spleen. None of the THXB mice developed hypersensitivity to the footpad test antigen. The uncharacteristic Listeria growth pattern in the T-cell-depleted spleen has been explained by the presence of a stimulated population of macrophages within that organ (1). The nonspecifically activated phagocytic cells limited the growth of the bacterial population to nonlethal proportions despite the absence of a T-cell-mediated immune response (2). Mice exposed to a sublethal dose (400 rads) of whole-body irradiation 24 h before the Listeria challenge showed a lack of resistance similar to that seen in the tilorone-treated mice (Fig. 1) . Irradiation of the host before the normally sublethal challenge potentiated the lethality of this organism so that 100% of the irradiated, infected mice died within 5 days. None of the irradiated mice developed detectable levels of delayed hypersensitivity.
Tilorone treatment of T-cell-depleted mice. A group of THXB and sham-thymectomized B6D2 mice were treated orally with 100 mg of tilorone per kg and infected 24 h later with 2 x 103 viable L. monocytogenes. The combined liver and spleen counts observed in the Tcell-depleted and control mice treated with the drug both increased at essentially the same rate, resulting in a 100% mortality rate for both groups by day 5. On the other hand, none of the untreated THXB mice or the normal controls died as a result of the Listeria challenge (Fig. 2) .
Growth of S. enteritidis in tiloronetreated mice. Normal mice were treated with tilorone and 24 h later were challenged with about 103 viable Salmonella (0.1 LD50). The viability of the challenge inoculum increased by about 5 logs over a 4-day period, resulting in 100% mortality in the treated mice. Control mice showed a 1,000-fold increase in viability over the first 5 days of the experiment, followed by the normal immune decline (Fig. 3) . The tiloronetreated mice failed to develop a delayed hypersensitivity response to the Salmonella test antigen, whereas the controls showed excellent footpad responses by day 4. Growth curves for S. enteritidis introduced into T-cell-depleted mice were very different from those seen in the tilorone-treated mice. The slowed growth rate in vivo was consistent with the presence of activated macrophages within the T-cell-depleted host. On the other hand, sublethally irradiated mice provided a Salmonella growth curve and mortality rate similar to those seen in the tilorone-treated host (Fig. 3) .
Histologically, the S. enteritidis-infected mice (examined after four oral doses of tilorone) showed an almost complete absence of granuloma formation within the heavily infected livers and spleens. A clear-cut cellular response was observed in the livers of the Salmonella-infected control mice (Fig. 4) . Evidence of tissue toxicity was found in the tilorone-treated infected mice, and this was presumed to be due to endotoxin (Fig. 5) . If the mice were treated daily with tilorone (100 mg/kg), early growth was not affected but the antituberculous response was largely ablated (Fig. 5) , as was the development of tuberculin hypersensitivity. A substantial immediate (3-h) hypersensitivity to the PPD injection was seen in the tilorone-treated mice, however.
In a subsequent study, mice were treated daily with tilorone for increasing time intervals ranging from 1 to 28 days, and the effect of the various regimens was compared in terms of the BCG growth curves (Fig. 6 ). Mice receiving a single oral dose of 100 mg/kg, as well as those with seven daily treatments, showed little change in the BCG growth pattern compared to that observed in untreated controls. As the treatment period was prolonged, the viable counts for the spleen and lung homogenates tended to remain constant with little sign of any immune decline (Fig. 6) . However, after a period of 2 weeks without further tilorone treatment, the BCG viable counts began to decline slowly, suggesting that the suppressive effect of the drug was quite short-lived (Fig. 6) . were not eliminated from the tissues, and viable counts carried out after 60 days showed a 10,000-fold increase within the lungs (Fig. 7) . Growth in the liver and spleen was much less prolific, and after an early phase of growth, the counts remained relatively constant for many weeks with little sign of any immune response. These mice developed an early tuberculin hypersensitivity which was later supplanted by a characteristic tuberculin anergy which continued throughout the remainder of the study.
Daily treatment of the Erdman-challenged mice with tilorone resulted in an ablation of the immune response in the liver and spleen, and virtually all of the mice died before day 90. None of the treated mice developed detectable levels of tuberculin hypersensitivity, although they did exhibit a substantial immediate (3-h) hypersensitivity response to the PPD (Fig. 7) . sensitized by the subcutaneous or the intravenous route (Table 1 ). The immediate (3-h) hypersensitivity response was not greatly affected, however.
Effect of tilorone on peripheral leukocyte counts. Daily oral treatment of normal B6D2 mice with 100 mg of tilorone per kg resulted in a 10-fold drop in the total leukocyte count within 24 h. Some counts represented only 5% of the control values. However, of these cells, 80 to 85% morphologically resembled small lymphocytes (Fig. 8) . Mice receiving only one dose of drug showed a substantial recovery in leukocyte counts within 3 days. However, continued daily treatment resulted in continued depression in total leukocytes for up to 7 days. Most of the cells present in the circulation after six daily doses of tilorone appeared to be small lymphocytes (Fig. 8) . Examination of these cells by appropriate fluorescence staining indicated that they consisted almost entirely of B-cells (86%); in the untreated animals, on the other hand, approximately one third of the small-lymphocyte population carried the immunoglobulin G surface marker ( Table 2 ). The T-cell population declined to virtually undetectable numbers over the 6-day treatment period. Over this same treatment period, the number of large and medium lymphocytes in the blood showed little change. Circulating monocyte and polymorphonuclear leukocyte counts both declined sharply in the drug-treated mice and fell to only a few hundred cells per cubic millimeter representing less than 5% of control values. The effect of this daily tilorone treatment bore a number of similarities to that seen after a sublethal dose of irradiation (Fig. 8) . However, the extent of the drop in all of the peripheral leukocytes was greater and more prolonged than that seen in the tilorone-treated animals.
DISCUSSION
Tilorone affects many T-cell-mediated responses generated against both replicating and Lt is interest-sion of an antitumor immunity (16) . Tilorone esponses are also markedly suppressed the T-cell-mediated humoral re-anti-Listeria responses in singly dosed mice in 2). Multiple which a 1,000-fold increase in Listeria virulence i and organ was observed (10) . This increase was largely graft-versu;3-ascribed to a T-cell depletive effect seen in multhe expre tiply treated rats and mice (11, 12) . However, this drug not only brought about a substantial drop in the peripheral blood small-lymphocyte counts, but also resulted in a significant drop (P < 0.01) in both monocyte and polymorphonu-A clear phagocyte counts (Fig. 8) . Acquired resistance to Listeria and Salmonella infections depends upon the entry of large numbers of immunologically activated macrophages into the developing lesion (4). Activation may be prevented if the mobilization of either T-cells or blood monocytes is temporarily blocked by the tilorone treatment. The shape of the growth curves obtained in the tilorones treated mice ( Fig. 1 and 3 (Fig. 2) . Since T-cell-depleted mice are known to have enhanced macrophage activity (1), it seems reasonable to assume that the daily tilo-C rone treatment somehow interfered with the production or deployment or both of these partially activated macrophages. Histological examination of the tiloronetreated, Salmonella-infected mice revealed an almost complete lack of cellular infiltration within the heavily infected liver (Fig. 4) . Studies with BCG-infected, T-cell-depleted mice indicated that although there was an almost com- 4 5 plete absence of cells morphologically resembling small lymphocytes in the lung tubercles,
Its from mice the lesions contained increasing numbers of radiation (A), monocytes and foamy macrophages (15 (Fig. 5) . The reduced mononuclear cell response in the drug-treated host was also responsible for the almost complete lack of delayed hypersensitivity shown by these animals (Fig. 1, 3, and 5 ). This is consistent with the complete absence of T-lymphocytes from the peripheral blood of multiply treated mice (Table 2 ). This reduced number of T-cells in the blood of tilorone-treated mice was offset by a greatly increased B-cell count, which rose to 85 to 90% of the small-lymphocyte population in mice receiving six daily doses of tilorone. These changes are in agreement with earlier studies by Raychaudhuri and Megel (18) . Presumably, there were still sufficient residual helper T-cells present in the host to bring about the observed enhanced humoral (immediate hypersensitivity) response ( Fig. 1 and 3) . The present study indicates that tilorone affects other cells besides the T-lymphocyte population, and further detailed studies of the kinetics of the mononuclear cell responses after repeated tilorone treatments will be needed before the cellular responses to this drug can be fully evaluated.
